NexImmune Inc. NexImmune Receives IND Clearance for Phase 1/2 trial in Acute Myeloid Leukemia / Myelodysplastic Syndrome ND clearance enables commencement of clinical trial to evaluate NEXI-001 in AML/MDS patients…
Read More
NexImmune Inc. NexImmune Receives IND Clearance for Phase 1/2 trial in Acute Myeloid Leukemia / Myelodysplastic Syndrome ND clearance enables commencement of clinical trial to evaluate NEXI-001 in AML/MDS patients…
Poseida Therapeutics, Inc. Poseida Therapeutics Appoints Kerry Ingalls as Chief Operating Officer October 10, 2019
Rapha Capital and ControlRad, Inc. Rapha Capital Management Participates in Series B Financing for ControlRad, Inc. Led by Questa Capital October 2, 2019